Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860954 | 0.79 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL1784617 | 0.78 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL5615920 | 0.76 | CYP3A4 (0.36) | CYP3A4LPAR3LPAR1LPAR2NPC1 | |
| SCHEMBL19386970 | 0.75 | CYP3A4 (0.45) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL4609562 | 0.72 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL28674444 | 0.70 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL17878594 | 0.69 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL17878591 | 0.69 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL17848859 | 0.69 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL3067605 | 0.69 | AKT1 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | CYP3A4 3756/4885LPAR3 2783/4885LPAR1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.